New York, New York - June 13, 2012 (Investorideas.com Newswire)
Investorideas.com, an investor research portal specializing in sector
research including biotech and pharma stocks, issues a news alert and
company snapshot for Aethlon Medical (OTCBB:AEMD)
, following news issued yesterday by the Company . Featuring commentary
authored by Chairman and CEO, Jim Joyce on "Cancer Research Discovery -
Melanoma Exosomes Fuel Organ Metastasis".
Aethlon Medical (OTCBB:AEMD) develops medical devices to address needs in cancer, infectious disease, and other life-threatening conditions.
"Our first research into cancer-secreted exosomes was driven by the
curiosity that exosomes seemed to carry a unique high mannose signature
that is found on the surface of glycoproteins that coat infectious viral
pathogens. This signature happened to be the targeted binding site of
the affinity agent immobilized in our Hemopurifier®, and provides the
basis for our ability to selectively capture HCV, HIV, and a
broad-spectrum of other viruses. In well-studied viruses such as HIV, we
knew that surface glycoproteins can shed to trigger apoptosis or
programmed cell death of immune cells. Therefore, it made sense to us
that exosomes might have these same immunosuppressive properties.
However, at the time we initiated our research, the medical community
consensus was that exosomes were nothing more than cellular trash bags
with no meaningful biologic function. In fact, there were only a handful
of researchers with exosome focused research programs. This is no
longer the case. Many cancer research institutes are now pursuing
exosome driven initiatives as cancer-secreted exosomes have since been
verified to play a significant role in the invasion of the immune system
in cancer patients. Additionally, researchers now understand how
exosomes contribute to the development of tumor angiogenesis as a
mechanism for cancer to survive. The harmful role of exosomes is also
being identified in other life threatening conditions, including sepsis,
a disease we are studying under contract with the Defense Advanced Research Projects Agency (DARPA).
To date, we have demonstrated the ability to capture exosomes
underlying a variety of cancers. As related to the discoveries by the
Weill Cornell team, we fortuitously disclosed in September of 2010 that
our Aethlon Hemopurifier® was able to capture exosomes derived from
individuals with metastatic melanoma in a pre-clinical study. At
present, we are fully focused on participating in a response to a new
DARPA contract opportunity, expanding our HCV treatment studies, and
preparing the resubmission of a investigational device exemption to FDA.
Once these objectives have been advanced,
we plan to discuss a potential melanoma treatment study that a U.S.
based cancer research institute has proposed to conduct as a result of
the Weill Cornell discoveries."
Full News:
http://www.investorideas.com/CO/AEMD/news/2012/06121.asp
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative
medical devices that address unmet medical needs in cancer, infectious
disease, and other life-threatening conditions. Our Aethlon ADAPT™
System is a revenue-stage technology
platform that provides the basis for a new class of therapeutics that
target the selective removal of disease enabling particles from the
entire circulatory system. The Aethlon ADAPT™ product pipeline includes
the Aethlon Hemopurifier® to address infectious disease and cancer;
HER2osome™ to target HER2+ breast cancer, and a medical device being
developed under a contract with the Defense Advanced Research Projects
Agency (DARPA) that would reduce the incidence of sepsis in
combat-injured soldiers and civilians. For more information, please
visit www.aethlonmedical.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader
in investor stock research by sector. Sectors we cover include; water
and renewable energy stocks, biotech stocks, mining and gold stocks,
energy stocks, natural gas stocks, tech (includes cloud and social
networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and stock alerts at Investorideas.com
Research biotech stocks at the Biotech stocks Directory
Become an Investorideas.com Member
http://www.investorideas.com/membership/
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure :
The Investorideas.com is a third party publisher of news and research
Our sites do not make recommendations, but offer information portals to
research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell
products or securities. This site is currently compensated by featured
companies, news submissions and online advertising. Disclosure
investorideas.com is compensated by AEMD for news publication at
Investorideas.com and syndicated partners: four thousand eight hundred
fifty for six months
BC Residents and Investor Disclaimer: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com
No comments:
Post a Comment